Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest biopharmaceuticals Stories

2014-04-11 08:24:18

LONDON, April 11, 2014 /PRNewswire/ -- ThioBridge(TM) linker to attach different payloads to a range of antibodies PolyTherics Limited ("PolyTherics"), a provider of technologies and services to enable the development of better biopharmaceuticals, today announced an extension to its ThioBridge(TM) antibody drug conjugate ("ADC") collaboration with MacroGenics Inc (NASDAQ: MGNX), a US biotechnology company developing innovative medicines utilizing its next...

2014-04-08 04:22:04

- Debio 0932 demonstrated anti-tumor activity and synergy with various SOC agents in in vitro and xenograft models of NSCLC and RCC - LAUSANNE, Switzerland and LEXINGTON, Mass., April 8, 2014 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription...

2014-03-27 12:30:47

LONDON, March 27, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Global Healthcare Cold Chain Logistics Market Report & Forecast (2013-2018) Driven by a strong growth in the sales of temperature sensitive healthcare products, the demand for cold chain logistic services is currently experiencing explosive growth. IMARC Group, one of the world's leading research and advisory firms, finds that the total size of the healthcare cold chain logistic...

2014-03-06 04:23:27

LAUSANNE, Switzerland, March 6, 2014 /PRNewswire/ -- Debiopharm Group(TM)(Debiopharm), a Swiss-based global biopharmaceutical group of companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investments, has announced its decision to expand and optimize activities at Debiopharm Research & Manufacturing S.A., its industrial development and production facility in Martigny (Valais, Switzerland), through acquisition of industrial...

2014-01-30 12:28:13

PRINCETON, N.J., Jan. 30, 2014 /PRNewswire/ -- Novo Nordisk (NYSE: NVO), a global healthcare company with 90 years of innovation and leadership in diabetes care, announced the promotion of Eddie Williams to senior vice president of biopharmaceuticals, effective February 1, 2014. (Logo: http://photos.prnewswire.com/prnh/20110414/NY80976LOGO) "Our biopharmaceutical business will be increasingly important to our growth in the U.S. as we apply the protein expertise developed through...

2014-01-08 04:21:06

LAUSANNE, Switzerland, January 8, 2014 /PRNewswire/ -- Spinomix SA, a Swiss company advancing molecular diagnostic through innovative sample preparation technologies and Debiopharm Group(TM)(Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs including oncology as well as companion diagnostics, today announced the successful achievement of a second development milestone on Spinomix' two proprietary...

2013-11-06 16:30:05

DUBLIN, Ireland, November 6, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/mdkxf2/biopharmaceuticals) has announced the addition of the "Biopharmaceuticals - A Global Market Overview" [http://www.researchandmarkets.com/research/mdkxf2/biopharmaceuticals ] report to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Biopharmaceuticals market, estimated at US$199.7 billion...

2013-10-24 12:26:35

GENEVA and LAUSANNE, Switzerland, October 24, 2013 /PRNewswire/ -- Atheris Laboratories, a world leading company in venom-based drug discovery and lead optimization, and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs including oncology along with companion diagnostics, today announced the signature of a collaboration agreement regarding the Atheris "Reverse-Discovery"(TM) lead...

2013-10-22 08:33:17

Designed to target advanced metastatic renal cell carcinoma, the study will determine the maximum tolerated dose of Debio 0932 in combination with everolimus LAUSANNE, Switzerland and LEXINGTON, Massachusetts, October 22, 2013 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a...

2013-10-07 04:21:07

SINGAPORE and LAUSANNE, Switzerland, October 7, 2013 /PRNewswire/ -- The Agency for Science, Technology and Research (A*STAR)'s Experimental Therapeutics Centre (ETC), a center of excellence to advance and accelerate drug discovery in Singapore, and Debiopharm Group(TM) (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology as well as companion diagnostics, today...